CAREERS AT BIOMARIN
Our focus on rare disease gives us the rare opportunity to truly impact lives.
Learn More about careers with BioMarin ⌃
OUR MOTIVATION
We are inspired and driven everyday by stories like Sheri’s.
Learn More about Sheri ⌃
Patient & Community Support
Treatment is only the beginning.
We are committed to the communities we treat beyond the therapies
OUR PIPELINE
We take on the biggest challenges in rare disease.
Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it
-
April 15, 2021BioMarin Announces New and Updated Data at 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and Potential Treatment Choice
-
April 13, 2021BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET
-
March 20, 2021BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society’s Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide
-
March 8, 2021BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
-
March 3, 2021BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia
-
February 25, 2021BioMarin Announces Fourth Quarter and Record Full-year 2020 Financial Results and Corporate Updates
-
February 24, 2021BioMarin to Participate in Four Upcoming Virtual Investor Conferences
-
November 17, 2020BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence